Richards Group (RIC) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
29 Oct, 2026Executive summary
Q3 revenue grew 2%, primarily on acquisitions; PharmaSystems contributed to a 1.8% overall increase.
Financial highlights
Gross margins grew 6.5% on stronger Healthcare mix.
Segment performance
Organic Healthcare revenue rose 6.3%, with strength in Pharmacy and Aesthetic; growth was driven by consumables and low-price capital equipment.
Packaging revenue fell 7.3%, compared with a 14.4% decline in H1.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Richards Group
- Healthcare-led growth, major acquisitions, and global expansion define a transformative year.RIC
Q4 2025 - Healthcare growth and margin gains drove higher profits despite packaging headwinds.RICQ2 2026
- Higher-margin mix and healthcare gains offset weak food & beverage, boosting Q2 profit and cash flow.RICQ2 2024
- Revenue and net income fell in Q3, but strong cash flow supported debt reduction and dividends.RICQ3 2024
- Revenue up 2.9% year-over-year, but net income down on higher costs and exceptional items.RICQ1 2025
- Revenue up 2.7% in H1 2025, but net income fell 58% amid tariffs and higher costs.RICQ2 2025
- Q3 revenue up 11.1% on acquisitions and healthcare, but net income fell on higher costs and one-time items.RICQ3 2025
- Revenue down 4.3% but margins and cash flow strong; acquisitions to drive 2025 growth.RICQ4 2024
- Healthcare and OEM growth lifted revenue and margins, but EBITDA was flat amid rising OpEx.RICQ1 2026